CervoMed Strengthens Board with Appointment of Life Sciences Business Strategy Leader David Quigley

Core Insights - CervoMed Inc. has appointed David Quigley to its Board of Directors, bringing extensive experience in business strategy and life sciences [1][2] - The appointment is strategic as CervoMed prepares for Phase 3 trials and commercialization of its lead drug candidate, neflamapimod, targeting dementia with Lewy bodies (DLB) [1][2] - DLB is a significant health issue with no approved treatments in the U.S. or EU, affecting millions globally [3][4] Company Overview - CervoMed is a clinical-stage biotechnology company focused on developing treatments for age-related brain disorders [4] - The lead drug candidate, neflamapimod, aims to restore communication between brain cells by inhibiting a key enzyme involved in inflammation and neurodegeneration [4] - The company recently completed a successful Phase 2b trial for neflamapimod in DLB patients and plans to initiate a global Phase 3 trial in mid-2026 [4] Industry Context - DLB is the second most common progressive dementia after Alzheimer's disease, characterized by cognitive decline, visual hallucinations, and motor symptoms similar to Parkinson's disease [3] - Current standard-of-care therapies for DLB only provide temporary symptom relief, highlighting the need for effective treatments [3]